Status:
COMPLETED
Effect of Diltiazem on Pharmacokinetics of BMS-914392
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
PRA Health Sciences
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the effects of diltiazem on the pharmacokinetics of single-dose BMS-914392 in healthy subjects.
Detailed Description
Protocol designed to evaluate the potential for a drug-drug interaction
Eligibility Criteria
Inclusion
- Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
- Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy
Exclusion
- Current or recent (within 3 months of study drug administration) gastrointestinal disease
- Current or history of neurological diseases or psychiatric disorders and cardiovascular diseases
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01211808
Start Date
September 1 2010
End Date
October 1 2010
Last Update
February 2 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pra International
Lenexa, Kansas, United States, 66219